Anti-HER-2 immunoglobulins were analyzed for binding to native HER-2 molecules on the surface of human breast cancer cells BT-474 by means of indirect immunofluorescence followed by flow cytometry or by binding to HER-2 extracellular domain (ECD) in ELISA. Here, ERBB2 is linked to breast cancer.